Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 6 of 6

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

NVK002 low-dose atropine 0.01% produced clinically meaningful myopia control over 3 years in the CHAMP phase 3 clinical trial for treatment of pediatric myopia progression

Houman David Hemmati; Tung Fong; Simon Chandler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2743.

ARVO Annual Meeting Abstract June 2024

The CHAMP phase 3 clinical trial of NVK002 low-dose atropine for treatment of pediatric myopia progression: A time-to-event analysis

Simon Chandler; Tung Fong; Houman Hemmati

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2742.

ARVO Annual Meeting Abstract June 2024

NVK002 low-dose atropine 0.01% maintains myopia control during a fourth year of dosing and discontinuation does not cause rebound myopia progression

Karla Zadnik; Houman Hemmati; Tung Fong; Simon Chandler

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):428.

ARVO Annual Meeting Abstract June 2023

Impact of confounding factors on long term myopia trials: learnings from the CHAMP study

Simon Chandler; Tung Fong; Eric Lang; Houman D Hemmati

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4963.

ARVO Annual Meeting Abstract June 2023

Efficacy of NVK002 low-dose atropine for treatment of pediatric myopia progression over 24 months: Comparison of CHAMP vs. other published trials.

Houman D Hemmati; Tung Fong; Eric Lang; Simon Chandler

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4962.

ARVO Annual Meeting Abstract June 2023

Low-dose atropine for treatment of pediatric myopia progression: a double-masked, placebo-controlled, randomized trial of 3-year efficacy and safety

Karla Zadnik; Erica Schulman; Daniel Ian Flitcroft; Jennifer Swingle Fogt; Louis C Blumenfeld; Tung Fong; Eric Lang; Houman D Hemmati; Simon Chandler

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3306.

Advertisement